Christoph Kalis

Title: Christoph Kalis: Innovator in Immunopathology Treatment

Introduction

Christoph Kalis is a notable inventor based in Gundelfingen, Germany. He has made significant contributions to the field of immunopathology through his innovative research and patenting efforts. His work focuses on the use of inhibitors of the activity or function of PI3K, which has implications for treating various diseases.

Latest Patents

Kalis holds a patent for the use of inhibitors of the activity or function of PI3K. This invention relates to new uses of PI3K inhibitors that exhibit an inhibitory action on the PI3K isoform delta. The patent addresses the treatment of immunopathology in subjects suffering from diseases such as malaria, leishmaniasis, trypanosomiasis, toxoplasmosis, and neurocysticercosis. The mechanism involves the functional inhibition of TLR9 in the infected subject.

Career Highlights

Christoph Kalis is currently associated with Novartis AG, a leading global healthcare company. His role at Novartis has allowed him to further his research and development efforts in the pharmaceutical industry. Kalis's work is characterized by a commitment to advancing medical treatments and improving patient outcomes.

Collaborations

Kalis has collaborated with esteemed colleagues, including Nigel Graham Cooke and Paulo Antonio Fernandes Gomes Dos Santos. These collaborations have enriched his research and contributed to the development of innovative solutions in the field of immunopathology.

Conclusion

Christoph Kalis is a prominent inventor whose work in immunopathology has the potential to transform treatment approaches for various diseases. His patent on PI3K inhibitors showcases his dedication to advancing medical science and improving health outcomes.